These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19804704)

  • 1. [Angiotensin converting enzyme inhibitors and calcium antagonists: a synergistic action for a better prevention of cardiovascular events].
    Boutouyrie P
    Therapie; 2009; 64(4):241-8. PubMed ID: 19804704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
    Widimský J
    Vnitr Lek; 2009 Feb; 55(2):123-30. PubMed ID: 19348394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Burnier M; Pruijm M; Wuerzner G
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
    Borghi C; Morbini M; Cicero AF
    J Cardiovasc Med (Hagerstown); 2015 May; 16(5):390-9. PubMed ID: 25590639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
    Gosse P
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Angiotensin converting enzyme inhibitor and calcium antagonist combination. Which place in patients with a stable coronary artery disease?].
    Lorgis L; Richard C; Gudjoncik A; Zeller M; Buffet P; L'Huillier I; Cottin Y
    Therapie; 2011; 66(1):17-24. PubMed ID: 21466773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulse pressure reduction and cardiovascular protection.
    Laurent S; Tropeano AI; Boutouyrie P
    J Hypertens Suppl; 2006 May; 24(3):S13-8. PubMed ID: 16723861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent blood pressure control: potential consequences for outcome.
    Leenen FH
    Can J Cardiol; 1999 May; 15 Suppl C():13C-18C. PubMed ID: 10380687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2.
    Ekbom T; Linjer E; Hedner T; Lanke J; De Faire U; Wester PO; Dahlöf B; Scherstén B
    Blood Press; 2004; 13(3):137-41. PubMed ID: 15223721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ASCOT blood pressure-lowering arm--study of effects of two BP-lowering regimens in hypertensive patients with cardiovascular risk factors.
    Cardiovasc J S Afr; 2005; 16(2):124, 126-7. PubMed ID: 15915281
    [No Abstract]   [Full Text] [Related]  

  • 19. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Old or new antihypertensives--which are better?].
    Schrader J; Kulschewski A
    MMW Fortschr Med; 2005 Mar; 147(13):36-7, 39-40. PubMed ID: 15832760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.